Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk PatientsThe MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) Trial
Christie M. Ballantyne, MD, FACC*,*,
Joel S. Raichlen, MD, FACC and
Valerie A. Cain, MS
* Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas
Clinical Development, AstraZeneca, Wilmington, Delaware.
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Patterns of ApoB Versus LDL-C Among All Patients Before and After Statin Therapy
(A) All patients untreated (baseline). (B) All patients on statin therapy. Horizontal lines show the upper threshold of the LDL-C goal of <100 mg/dl, and vertical lines show the upper threshold of the proposed secondary apoB goal of <90 mg/dl. Colors of data points denote treatment during the final 8 weeks of the trial of each patient. ApoB = apolipoprotein B; ATV = atorvastatin; LDL-C = low-density lipoprotein cholesterol; RSV = rosuvastatin; SMV = simvastatin.
|
|
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Patterns of ApoB Versus Non–HDL-C Among All Patients Before and After Statin Therapy
(A) All patients untreated (baseline). (B) All patients on statin therapy. Horizontal lines show the upper threshold of the non–HDL-C goal of <130 mg/dl, and vertical lines show the upper threshold of the proposed secondary apoB goal of <90 mg/dl. Colors of data points denote treatment during the final 8 weeks of the trial of each patient. HDL-C = high-density lipoprotein cholesterol; other abbreviations as in Figure 1.
|
|
|
